The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1).

By M. Garcia-Calvo, Jeanmarie Lisnock, H. Bull, B. Hawes, D. Burnett, M. Braun, J. Crona, H. Davis, D. Dean, P. Detmers and 15 more. Proceedings of the National Academy of Sciences of the United States of America, 2005

778 citations recorded by the source corpus.

Subfields: Infectious Diseases, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/245176279477091773b05520d73fb8dc5bb665f2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Surgery

Citations in the corpus

Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. (2006, background): “Despite the fact that ezetimibe, a known inhibitor of intestinal absorption of both animal- and plant-derived sterols, selectively blocks NPC1L1 (100), this drug also corrects the impaired fractional absorption and plasma levels of sterols in patients with sitosterolemia (301) and in the G5G8 / mice”
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (2017, background): “Ezetimibe inhibits intestinal absorption of cholesterol by binding to the NPC1L1 transporter protein.(37) Among the 18 144 persons with acute coronary syndrome enrolled in the IMPROVE-IT trial, treatment with ezetimibe plus a statin vs.”
Developing medicines that mimic the natural successes of the human genome: lessons from NPC1L1, HMGCR, PCSK9, APOC3, and CETP. (2015, background): “Experiments in cells and mice confirmed that ezetimibe tightly binds to and blocks NPC1L1, and targeted deletion of Npc1l1 in mice lowered plasma cholesterol and reduced atherosclerosis (8,9).”